The increasing femininization of the AIDS pandemic demands that we develop new approaches to HIV prevention that allows women to take control of their reproductive health. In the absence of effective HIV vaccines the two most promising approaches are pre-exposure prophylaxis with antiretrovirals (PREP) or topical application of microbicides. Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections (STIs) including HIV-1. Currently, seven candidate microbicides are in clinical development and three products are being evaluated in large-scale phase 2B/3 effectiveness studies. Initial data from these trials will be available within the next 1–2 years and it is feasible that there could be one or more licensed microbicides by the end of the decade. The first generation of surfactant microbicides had a relatively non-specific mechanism of...


Trial Site Serodiscordant Couple Cellulose Sulfate Microbicide Trial Real Time Access 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Abbas, U. L., Anderson, R. M., & Mellors, J. W. (2007). Potential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settings. PLoS ONE, 2(9), e875.CrossRefPubMedGoogle Scholar
  2. Alliance for Microbicide Development (2006). Microbicide research and development database. (Accessed December 31, 2006);
  3. Auvert, B., Taljaard, D., Lagarde, E., Sobngwi-Tambekou, J., Sitta, R., & Puren, A. (2005). Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Medicine, 2(11), e298.CrossRefPubMedGoogle Scholar
  4. Bailey, R. C., Moses, S., Parker, C. B., Agot, K., Maclean, I., Krieger, J. N., Williams, C. F., Campbell, R. T., & Ndinya-Achola, J. O. (2007). Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet, 369(9562), 643–656.CrossRefPubMedGoogle Scholar
  5. Barnhart, K. T., Pretorius, E. S., Timbers, K., Shera, D., Shabbout, M., & Malamud, D. (2004). In vivo distribution of a vaginal gel: MRI evaluation of the effects of gel volume, time and simulated intercourse. Contraception, 70(6), 498–505.CrossRefPubMedGoogle Scholar
  6. Blower, S., Bodine, E., Kahn, J., & McFarland, W. (2005). The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS, 19(1), 1–14.CrossRefPubMedGoogle Scholar
  7. Coplan, P. M., Mitchnick, M., & Rosenberg, Z. F. (2004). Public health. Regulatory challenges in microbicide development. Science, 304(5679), 1911–1912.CrossRefPubMedGoogle Scholar
  8. Corey, L., Wald, A., Celum, C. L., & Quinn, T. C. (2004). The effects of Herpes Simplex Virus-2 on HIV-1 acquisition and transmission: a review of two overlapping epidemics. Journal of Acquired Immune Deficiency Syndromes, 35(5), 435–445.CrossRefPubMedGoogle Scholar
  9. Cunningham, C. K., Chaix, M. L., Rekacewicz, C., Britto, P., Rouzioux, C., Gelber, R. D., Dorenbaum, A., Delfraissy, J. F., Bazin, B., Mofenson, L., & Sullivan, J. L. (2002). Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. The Journal of Infectious Diseases, 186(2), 181–188.CrossRefPubMedGoogle Scholar
  10. D'Cruz, O. J. & Uckun, F. M. (2004). Clinical development of microbicides for the prevention of HIV infection. Current Pharmaceutical Design, 10(3), 315–336.CrossRefPubMedGoogle Scholar
  11. Duerr, A., Wasserheit, J. N., & Corey, L. (2006). HIV vaccines: new frontiers in vaccine development. Clinical Infectious Diseases, 43(4), 500–511.CrossRefPubMedGoogle Scholar
  12. Eshleman, S. H. & Jackson, J. B. (2002). Nevirapine resistance after single dose prophylaxis. AIDS Reviews, 4(2), 59–63.PubMedGoogle Scholar
  13. Fauci, A. S. (2006). Twenty-five years of HIV/AIDS. Science, 313(5786), 409.CrossRefPubMedGoogle Scholar
  14. Garg, S., Kandarapu, R., Vermani, K., Tambwekar, K. R., Garg, A., Waller, D. P., & Zaneveld, L. J. (2003). Development pharmaceutics of microbicide formulations. Part I: preformulation considerations and challenges. AIDS Patient Care and STDs, 17(1), 17–32.CrossRefPubMedGoogle Scholar
  15. Garg, S., Tambwekar, K. R., Vermani, K., Kandarapu, R., Garg, A., Waller, D. P., & Zaneveld, L. J. (2003). Development pharmaceutics of microbicide formulations. Part II: formulation, evaluation, and challenges. AIDS Patient Care and STDs, 17(8), 377–399.CrossRefPubMedGoogle Scholar
  16. Grant, R. M., Buchbinder, S., Cates, W., Jr., Clarke, E., Coates, T., Cohen, M. S., Delaney, M., Flores, G., Goicochea, P., Gonsalves, G., Harrington, M., Lama, J. R., MacQueen, K. M., Moore, J. P., Peterson, L., Sanchez, J., Thompson, M., & Wainberg, M. A. (2005). AIDS. Promote HIV chemoprophylaxis research, don't prevent it. Science, 309(5744), 2170–2171.CrossRefPubMedGoogle Scholar
  17. Gray, R. H., Kigozi, G., Serwadda, D., Makumbi, F., Watya, S., Nalugoda, F., Kiwanuka, N., Moulton, L. H., Chaudhary, M. A., Chen, M. Z., Sewankambo, N. K., Wabwire-Mangen, F., Bacon, M. C., Williams, C. F., Opendi, P., Reynolds, S. J., Laeyendecker, O., Quinn, T. C., & Wawer, M. J. (2007). Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet, 369(9562), 657–666.CrossRefPubMedGoogle Scholar
  18. Haghighi, D. B. & Lashner, B. A. (2004). Left-sided ulcerative colitis. Gastroenterology Clinics of North America, 33(2), 271–84, ix.CrossRefPubMedGoogle Scholar
  19. Hillier, S. L., Moench, T., Shattock, R., Black, R., Reichelderfer, P., & Veronese, F. (2005). In vitro and in vivo: The Story of Nonoxynol 9. Journal of Acquired Immune Deficiency Syndromes, 39(1), 1–8.CrossRefPubMedGoogle Scholar
  20. Hu, J., Gardner, M. B., & Miller, C. J. (2000). Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. Journal of Virology, 74(13), 6087–6095.CrossRefPubMedGoogle Scholar
  21. Kim, H. N., Tabet, S. R., Corey, L., & Celum, C. L. (2005). Antiretroviral therapy for HIV-1 vaccine efficacy trial participants who seroconvert. Vaccine, 24(3), 532–9.PubMedGoogle Scholar
  22. Koblin, B., Chesney, M., Coates, T., & EXPLORE Study Team. (2004). Effects of a behavioural intervention to reduce acquisition of HIV infection among men who have sex with men: the EXPLORE randomised controlled study. Lancet, 364(9428), 41–50.Google Scholar
  23. Lard-Whiteford, S. L., Matecka, D., O'Rear, J. J., Yuen, I.S., Litterst, C., Reichelderfer, P., & International Working Group on Microbicides. (2004). Recommendations for the nonclinical development of topical microbicides for prevention of HIV transmission: an update. Journal of Acquired Immune Deficiency Syndromes, 36(1), 541–552.CrossRefPubMedGoogle Scholar
  24. Mantell, J. E., Myer, L., Carballo-Dieguez, A., Stein, Z., Ramjee, G., Morar, N. S., & Harrison, P. F. (2005). Microbicide acceptability research: current approaches and future directions. Social Science & Medicine, 60(2), 319–330.CrossRefGoogle Scholar
  25. Mauck, C., Rosenberg, Z., & Van Damme, L. (2001). Recommendations for the clinical development of topical microbicides: an update. AIDS, 15(7), 857–868.CrossRefPubMedGoogle Scholar
  26. Mills, E., Rachlis, B., Wu, P., Wong, E., Wilson, K., & Singh, S. (2005). Media reporting of tenofovir trials in Cambodia and Cameroon. BMC International Health & Human Rights, 5, 6.CrossRefGoogle Scholar
  27. Neurath, A. R., Strick, N., & Li, Y. Y. (2003). Water dispersible microbicidal cellulose acetate phthalate film. BMC Infectious Diseases, 3, 27.CrossRefPubMedGoogle Scholar
  28. Owen, D. H., Peters, J. J., & Katz, D. F. (2000). Rheological properties of contraceptive gels. Contraception, 62(6), 321–326.CrossRefPubMedGoogle Scholar
  29. Padian, N. S., van der, Straten A., Ramjee, G., Chipato, T., de, Bruyn G., Blanchard, K., Shiboski, S., Montgomery, E. T., Fancher, H., Cheng, H., Rosenblum, M., van der, Laan M., Jewell, N., & McIntyre, J. (2007). Diaphragm and lubricant gel for prevention of HIV acquisition in southern African women: a randomised controlled trial. Lancet, 370(9583), 251–261.CrossRefPubMedGoogle Scholar
  30. Poles, M. A., Elliott, J., Taing, P., Anton, P. A., & Chen, I. S. (2001). A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. Journal of Virology, 75(18), 8390–8399.CrossRefPubMedGoogle Scholar
  31. Pretorius, A., Timbers, K., Malamud, D., & Barnhart, K. (2003). Magnetic resonance imaging to determine the distribution of a vaginal gel: before, during, and after both simulated and real intercourse. Contraception, 66(6), 443–451.CrossRefGoogle Scholar
  32. Ramjee, G., Govinden, R., Morar, N. S., & Mbewu, A. (2007). South Africa's experience of the closure of the cellulose sulphate microbicide trial. PLoS Medicine, 4(7), e235.CrossRefPubMedGoogle Scholar
  33. Sawires, S. R., Dworkin, S. L., Fiamma, A., Peacock, D., Szekeres, G., & Coates, T. J. (2007). Male circumcision and HIV/AIDS: challenges and opportunities. Lancet, 369(9562), 708–713.CrossRefPubMedGoogle Scholar
  34. Severy, L. J., Tolley, E., Woodsong, C., & Guest, G. (2005). A framework for examining the sustained acceptability of microbicides. AIDS and Behavior, 9(1), 121–131.CrossRefPubMedGoogle Scholar
  35. Sexton, A., Drake, P. M., Mahmood, N., Harman, S. J., Shattock, R. J., & Ma, J. K. (2006). Transgenic plant production of Cyanovirin-N, an HIV microbicide. FASEB Journal, 20(2), 356–358.PubMedGoogle Scholar
  36. Shattock, R. J. (2006). Protection of macaques against rectal SIV challenge by mucosally-applied PMPA. Presented at Microbicides 2006, Cape Town, South Africa (Abstract OA15).Google Scholar
  37. Shattock, R. J. & Moore, J. P. (2003). Inhibiting sexual transmission of HIV-1 infection. Nature Reviews. Microbiology, 1(1), 25–34.CrossRefPubMedGoogle Scholar
  38. Stein, Z. A. (1990). HIV prevention: the need for methods women can use. American Journal of Public Health, 80(4), 460–462.CrossRefPubMedGoogle Scholar
  39. Tsai, C. C., Emau, P., Jiang, Y., Tian, B., Morton, W. R., Gustafson, K. R., & Boyd, M. R. (2003). Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Research and Human Retroviruses, 19(7), 535–541.CrossRefPubMedGoogle Scholar
  40. UNAIDS. (2006). 2006 Report on the global AIDS epidemic. Geneva.
  41. US Food and Drug Administration. (2006). Additional resources regarding drug development of topical microbicides. (Accessed December 31, 2006);
  42. Van Damme, L., Ramjee, G., Alary, M., Vuylsteke, B., Chandeying, V., Rees, H., Sirivongrangson, P., Mukenge-Tshibaka, L., Ettiegne-Traore, V., Uaheowitchai, C., Karim, S. S., Masse, B., Perriens, J., & Laga, M. (2002). Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet, 360(9338), 971–977.CrossRefPubMedGoogle Scholar
  43. Veazey, R. S., Klasse, P. J., Schader, S. M., Hu, Q., Ketas, T. J., Lu, M., Marx, P. A., Dufour, J., Colonno, R. J., Shattock, R. J., Springer, M. S., & Moore, J. P. (2005). Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature, 438(7064), 99–102.CrossRefPubMedGoogle Scholar
  44. Woolfson, A. D., Malcolm, R. K., Morrow, R. J., Toner, C. F., & McCullagh, S. D. (2006). Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. International Journal of Pharmaceutics, 325(1–2), 82–89.CrossRefPubMedGoogle Scholar

Copyright information

© Springer ScienceBusiness Media, LLC 2008

Authors and Affiliations

  • Ian McGowan
    • 1
  1. 1.University of Pittsburgh, School of MedicinePittsburghUSA

Personalised recommendations